Abstract
The majority of men with testicular germ cell tumours present with a painless testicular mass typically between 20 and 40 years of age. Staging includes measurement of serum tumour markers AFP, ß-hCG and LDH and imaging by computed tomography of the chest, abdomen and pelvis. Primary management consists of extirpation of the tumour-bearing testis and its cord (radical orchiectomy) through the inguinal approach. In doubtful cases intraoperative frozen section analysis may be considered. An organ sparing approach can be carefully considered in men with synchronous or metachronous bilateral TGCT or a tumour in solitary testicle, but this awaits wider acceptance. A contralateral testicular biopsy to rule out testicular intraepthelial neoplasia is recommended in high-risk patients (testicular volume <12 ml, age <30 years, history of cryptorchidism). In clinical stage I nonseminomatous TGCT, a risk adapted approach is recommended with active surveillance, primary chemotherapy with 2 cycles or nerve sparing retroperitoneal lymph node dissection (RPLND). Low volume metastatic disease (clinical stages IIA-B) associated with elevated tumour markers are best managed by primary systemic chemotherapy whereas patients with negative markers might be approached by active surveillance or by nerve sparing RPLND. Postchemotherapy RPLND remains an integral part of the multimodality treatment of advanced testicular cancer. Small indeterminate lesions less than 1 cm in diameter might be managed by active surveillance in men with good prognosis. In all other cases, all residual retroperitoneal lesions should be completely resected.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bosl GH, Goldman A, Lange PH, et al. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet. 1981;2(8253):970–3.
Nikzas S, Champion AE, Fox M. Germ cell tumors of testis: prognostic factors and results. Eur Urol. 1990;18:242–7.
Krege S, Albers P, Heidenreich A. The role of tumour markers in diagnosis and management of testicular germ cell tumours. Urologe A. 2011;50(3):313–21.
Krege S, Beyer J, Souchon R, Albers P, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008;53(3):478–96.
Albers P, Albrecht W, Algaba F, et al. EAU guidelines on testicular cancer: 2011 update. Eur Urol. 2011;60(2):e9–18.
Barentsz J, Takahashi S, Oyen W, et al. Commonly used imaging techniques for diagnosis and staging. J Clin Oncol. 2006;24:3234–44.
White PM, Adamson DJA, Howard GCW, et al. Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol. 1999;54:207–11.
Meyer CA, Conces DJ. Imaging of intrathoracic metastases of nonseminomatous germ cell tumors. Chest Surg Clin N Am. 2002;12:717–38.
Kreydin EI, Barrisford GW, Feldman AS, Preston MA. Testicular cancer: what the radiologist needs to know. Am J Roentgenol. 2013;200(6):1215–25.
de Wit M, Brenner W, Hartmann M, et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol. 2008;19(9):1619–23.
Huddart RA, O’Doherty MJ, Padhani A, Rustin GJ, et al. NCRI Testis Tumour Clinical Study Group. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 – the NCRI Testis Tumour Clinical Study Group. J Clin Oncol. 2007;25(21):3090–5.
Sobin LH, Wittekind CH, editors. UICC: TNM classification of malignant tumours. 7th ed. New York: Wiley-Liss; 2010.
International Germ Cell Cancer Collaborative Group (IGCCCG). The International Germ Cell Consensus Classification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol. 1997;15:594–603.
Holstein AF, Orlandini GE, Moller R. Distribution and fine structure of the lymphatic system in the human testis. Cell Tissue Res. 1979;200(1):15–27.
Husband JE, Koh D-M. Chapter 19: Testicular germ cell tumours. In: Husband JE, Reznek RH, editors. Imaging in oncology. 2nd ed. London: Taylor & Francis; 2004. p. 401–27.
Holtl L, Pescel R, Knapp R, et al. Primary lymphatic metastatic spread in testicular cancers occurs ventral to the lumbar vessels. Urology. 2002;59:114–8.
Williams MP, Cook JV, Duchesne GM. Psoas nodes: an overlooked site of metastasis from testicular tumours. Clin Radiol. 1989;40:607–9.
Ondrus D, Hornak M, Breza J, et al. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol. 2001;32:665–7.
Simmonds PD, Mead GM, Lee AHS, et al. Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Cancer. 1995;75:1018–24.
Leibovitch I, Little JS, Foster RS, et al. Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J Urol. 1996;155:952–4.
Elert A, Olbert P, Hegele A, et al. Accuracy of frozen section examination of testicular tumors of uncertain origin. Eur Urol. 2002;41:290–3.
Leroy X, Rigot JM, Aubert S, et al. Value of frozen section examination for the management of nonpalpable incidental testicular tumors. Eur Urol. 2003;44:458–60.
Weissbach L. Organ preserving surgery of malignant germ cell tumors. J Urol. 1995;153:90–3.
Heidenreich A, Weissbach L, Höltl W, et al. German Testicular Cancer Study Group. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol. 2001;166:2161–5.
Heidenreich A, Angerer-Shpilenya M. Organ-preserving surgery for testicular tumours. BJU Int. 2012;109(3):474–90.
Schmoll H-J, Jordan K, Huddart R, Laguna MP, et al. Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow up. Ann Oncol. 2009;20 Suppl 4:iv83–8.
Ethics Committee of the American Society for Reproductive Medicine. Ethics committee report: fertility preservation and reproduction in cancer patients. Fertil Steril. 2005;83(6):1622–8.
Loren AW, Mangu PB, Nohr Beck L, et al. Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.
Rorth M, Rajpert-De Meyts E, Andersson L, et al. Carcinoma in situ of the testis. Scand J Urol Nephrol. 2000;205 Suppl 6:166–86.
von der Maase H, Rohrt M, Waldbom-Jorgensen S, et al. Carcinoma in situ of the contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed). 1986;293:1398–401.
Dieckmann KP, Loy V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J Clin Oncol. 1996;14:3126–32.
van Casteren NJ, de Jong J, Stoop H, Steyerberg EW, et al. Evaluation of testicular biopsies for carcinoma in situ: immunohistochemistry is mandatory. Int J Androl. 2009;32:666–74.
Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol. 2007;51:175–83.
Fossa SD, Chen J, Schonfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst. 2005;97(14):1056–66.
Heidenreich A. Contralateral testicular biopsy in testis cancer: current concepts and controversies. BJU Int. 2009;104(9 Pt B):1346–50.
Chung P, Warde P. Stage I seminoma: adjuvant treatment is effective but is it necessary? J Natl Cancer Inst. 2011;103(3):194–6.
Schmoll HJ, Jordan K, Huddart R, Pes MP, et al. ESMO Guidelines Working Group. Testicular seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2010;21(5):40–6.
Warszawski N, Schmucking M. Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scan J Urol Nephrol. 1997;31(4):335–9.
Mosharafa AA, Foster RS, Leibovitch BC, et al. Is postchemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol. 2003;169:2126–8.
Pont J, Höltl W, Kosak D, et al. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. J Clin Oncol. 1990;8:16–9.
Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992;10:1762–8.
Heidenreich A, Sesterhenn IA, Mostofi FK, et al. Prognostic factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer. 1998;83:1002–11.
Albers P, Siener R, Kliesch S, Weissbach L, et al. German Testicular Cancer Study Group. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol. 2003;21(8):1505–12.
Perrotti M, Ankem M, Bancilla A, et al. Prospective metastatic risk assignment in clinical stage I nonseminomatous germ cell testis cancer: a single institution pilot study. Urol Oncol. 2004;22(3):174–7.
Leibovitch I, Foster RS, Kopecky KK, et al. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitative immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol. 1998;16:261–8.
Spermon JR, Roeleveld TA, van der Poel HG, et al. Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumors. Urology. 2002;59:923–9.
Oliver RT, Ong J, Shamash J, et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage I nonseminoma treated with adjuvant chemotherapy. Urology. 2004;63:556–61.
Maroto P, Garcia del Muro X, Aparicio J, et al. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol. 2005;16:1915–20.
Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol. 2009;181(2):627–32.
Atsü N, Eskiçorapçi S, Uner A, Ekici S, et al. A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours. BJU Int. 2003;92(1):32–5.
Rustin GJ, Mead GM, Stenning SP, et al. National Cancer Research Institute Testis Cancer Clinical Studies Group. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol. 2007;25(11):1310–5.
Kakiashvili DM, Zuniga A, Jewett MA. High risk NSGCT: case for surveillance. World J Urol. 2009;27(4):441–7.
Kollmannsberger C, Moore C, Chi KN, Murray N, et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol. 2010;21(6):1296–301.
Divrik RT, Akdogan B, Özen H, Zorlu F. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors – is shift to risk adapted policy justified? J Urol. 2006;176:1424–30.
Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol. 2005;23:2781–8.
Al-Tourah AJ, Murray N, Coppin C, et al. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant carcinoma nonseminomatous testicular cancer: a population based analysis from British Columbia. J Urol. 2005;174:2209–13.
Stephenson AJ, Bosl GJ, Bajorin DF, et al. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol. 2005;174:557–60.
Baniel J, Foster RS, Einhorn LH, et al. Late relapse of clinical stage I testicular cancer. J Urol. 1995;154:1370–2.
Yoon GH, Stein JP, Skinner DG. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle: an update. Urol Oncol. 2005;23:168–77.
Jewett MA, Kong YS, Goldberg SD, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol. 1988;139:1220–4.
Donohue JP, Thornhill JA, Foster RS, et al. Primary retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. Br J Urol. 1993;71:326–35.
Donohue JP, Foster RS, Rowland RG, et al. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990;144:287–91.
Nicolai N, Miceli R, Necchi A, et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol. 2010;58:912–8.
Rassweiler JJ, Scheitlin W, Heidenreich A, et al. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective. Eur Urol. 2008;54(5):1004–15.
Leibovitch I, Foster RS, Ulbright TM, Donohue JP. Adult primary pure teratoma of the testis. The Indiana experience. Cancer. 1995;75(9):2244–50.
Heidenreich A, Moul JW, McLeod DG, et al. The role of retroperitoneal lymphadenectomy in mature teratoma of the testis. J Urol. 1997;157(1):160–3.
Heidenreich A, Albers P, Hartmann M, et al. German Testicular Cancer Study Group. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol. 2003;169(5):1710–4.
Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicentric trial. J Clin Oncol. 2003;21(6):1101–6.
Logothetis CJ, Samuels ML, Selig DE, et al. Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report. J Urol. 1985;134:1127–30.
Horwich A, Stenning S. Initial chemotherapy for stage II testicular nonseminoma. World J Urol. 1994;12:148–50.
Weissbach L, Bussar-Maatz R, Flechtner H, et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol. 2000;37:582–94.
Sheinfeld J, Motzer RJ, Rabbani F, et al. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and II A nonseminomatous germ cell tumors. J Urol. 2003;170:1159–62.
Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med. 1987;317:1433–8.
Pizzocaro G, Monfardini S. No adjuvant chemotherapy in selected patients with pathological stage II nonseminomatous germ cell tumors of the testis. J Urol. 1994;131:677–80.
Steiner H, Muller T, Gozzi C, et al. Two cycles of cisplatin-based chemotherapy for low-volume retroperitoneal stage II nonseminomatous germ cell tumours. BJU Int. 2006;98:349–52.
Weissbach L, Hartlapp JH. Adjuvant chemotherapy of metastatic stage II non-seminomatous testis tumor. J Urol. 1991;146:1285–98.
Kennedy BJ, Torkelson JL, Fraley EE. Adjuvant chemotherapy for stage II nonseminomatous germ cell cancer of the testis. Cancer. 1994;73:1485–9.
Kondagunta GV, Sheinfeld J, Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol. 2004;22:464–7.
Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53(3):497–513.
Kollmannsberger C, Daneshmand S, So A, et al. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol. 2010;28(4):537–42.
Ehrlich Y, Brames MJ, Beck SD, et al. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol. 2010;28(4):531–6.
Pfister D, Busch J, Winter C, et al. Pathohistological findings in patients with nonseminomatous germ cell tumours who undergo postchemotherapy retroperitoneal lymph node dissection for small residual lesions. J Urol. 2011;185:e334.
Heidenreich A. Residual tumor resection following inductive chemotherapy in advanced testicular cancer. Eur Urol. 2007;51:299–301.
Besse B, Grunenwald D, Fléchon A, et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg. 2009;137(2):448–52.
Jacobsen NE, Beck SD, Jacobson LE, et al. Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? J Urol. 2010;184(3):949–53.
Winter C, Pfister D, Busch J, et al. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol. 2012;61(2):403–9.
Hendry WF, Norman AR, Dearnaley DP, et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94:1668–76.
Beck SD, Foster RS, Bihrle R, et al. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor ? Cancer. 2007;110:1235–40.
Heidenreich A, Pfister D, Witthuhn R, et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol. 2009;55(1):217–24.
Heidenreich A, Ohlmann C, Hegele A, Beyer J. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol. 2005;47(1):64–71.
McKiernan JM, Motzer RJ, Bajorin DF, et al. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology. 2003;62(4):732–6.
Sexton WJ, Wood CG, Kim R, Pisters LL. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol. 2003;169(4):1353–6.
Albers P, Ganz A, Hannig E, et al. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol. 2000;164(2):381–4.
Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2005;23(25):6149–56.
Logothetis CJ, Samuels ML, Trindade A, Johnson DE. The growing teratoma syndrome. Cancer. 1982;50:1629–35.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag London
About this chapter
Cite this chapter
Heidenreich, A. (2015). Testicular Cancer- Clinical Features, Staging and Surgical Management. In: Nargund, V., Raghavan, D., Sandler, H. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-482-1_28
Download citation
DOI: https://doi.org/10.1007/978-0-85729-482-1_28
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-481-4
Online ISBN: 978-0-85729-482-1
eBook Packages: MedicineMedicine (R0)